Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis

Boldrini, Luca; Romano, Angela; Chiloiro, G.; Corradini, Stefanie; Luca, V. De; Verusio, V.; D’Aviero, Andrea; Castelluccia, A.; Alitto, A.R.; Catucci, Francesco; Grimaldi, Gianmarco; Trapp, Christian; Hörner-Rieber, Juliane; Marchesano, D.; Frascino, V.; Mattiucci, Gian Carlo; Valentini, Vincenzo; Gentile, Piercarlo; Gambacorta, Maria Antonietta

doi:10.1186/s13014-023-02271-y

Cited by 5 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SBRT as salvage therapy for radiorecurrent prostate cancer has been used for more than 15 years [9] , [10] , [12] . Early case series were usually done with a Cyberknife treatment machine whereas newer studies included cohorts treated with C-arm Linacs or MR Linacs [10] , [19] , [42] , [43] , [12] , [13] , [14] , [15] , [16] , [17] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [58] , [59] , [60] , [61] , [62] , [63] , [64] . Of the 14 studies included in this meta -analysis, only three included patients that were exclusively treated on a Cyberknife [34] , [42] , [43] .…”

Section: Discussionmentioning

confidence: 99%

“…Noticeably, earlier studies on SBRT for radiorecurrent prostate cancer were often done using a Cyberknife treatment machine [9] , [10] , [12] , [13] , [14] , [15] , [16] . In the last years, however, there has been increasing evidence on prostate re-irradiation using a C-arm LINAC or a MR LINAC [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] as well as an increase in prospective data [24] , [30] , [33] , [34] , [26] , [27] , [28] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after initial definitive radiotherapy – A systematic review and meta-analysis of recent trials

Schröder,

Tang,

Lenffer

et al. 2024

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after initial definitive radiotherapy – A systematic review and meta-analysis of recent trials

Schröder,

Tang,

Lenffer

et al. 2024

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

“…Retrospective and preliminary studies have shown feasibility and tolerable toxicity in patients receiving total doses ranging from 25–40 Gy in five fractions. In such studies, no grade 2+ GU toxicity was observed, while grade 2+ GI toxicity occurred in 4 out of 18 patients (22.2%) [ 35 , 36 ]. Two patients were adopted with good tolerance but without substantial differences in GI toxicity compared to patients without online adaptation.…”

Section: Advantages Of Mrigrtmentioning

confidence: 99%

MRI-Guided Radiation Therapy for Prostate Cancer: The Next Frontier in Ultrahypofractionation

Benitez,

Steinberg,

Cao

et al. 2023

Cancers

View full text Add to dashboard Cite

Technological advances in MRI-guided radiation therapy (MRIgRT) have improved real-time visualization of the prostate and its surrounding structures over CT-guided radiation therapy. Seminal studies have demonstrated safe dose escalation achieved through ultrahypofractionation with MRIgRT due to planning target volume (PTV) margin reduction and treatment gating. On-table adaptation with MRI-based technologies can also incorporate real-time changes in target shape and volume and can reduce high doses of radiation to sensitive surrounding structures that may move into the treatment field. Ongoing clinical trials seek to refine ultrahypofractionated radiotherapy treatments for prostate cancer using MRIgRT. Though these studies have the potential to demonstrate improved biochemical control and reduced side effects, limitations concerning patient treatment times and operational workflows may preclude wide adoption of this technology outside of centers of excellence. In this review, we discuss the advantages and limitations of MRIgRT for prostate cancer, as well as clinical trials testing the efficacy and toxicity of ultrafractionation in patients with localized or post-prostatectomy recurrent prostate cancer.

show abstract

“…Noticeably, earlier studies on SBRT for radiorecurrent prostate cancer were often done using a Cyberknife treatment machine (9,10,(12)(13)(14)(15)(16). In the last years, however, there has been increasing evidence on prostate re-irradiation using a C-arm LINAC or a MR LINAC (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33).…”

Section: Introductionmentioning

confidence: 99%

Re-irradiation to the Prostate using stereotactic body radiotherapy (SBRT) after initial definitive Radiotherapy – A systematic review and Meta-analysis of recent trials

Schröder,

Tang,

Buchali

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: There is increasing data on re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after definite radiotherapy for prostate cancer. There has been increasing evidence on prostate re-irradiation using a C-arm LINAC or a MR LINAC in the last years. We therefore conducted this systematic review and meta-analysis on prostate re-irradiation including studies published from 2020-2023 to serve as an update on existing meta-analysis. Methods: We searched the Pubmed and Embase databases in October 2023 with queries including combinations of "repeat", "radiotherapy", "prostate", "re-irradiation", "reirradiation", "re treatment", "SBRT", "retreatment". Publication date was set to be from 2020 to 2023. There was no limitation regarding language. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. After data extraction, heterogeneity testing using I2. Afterwards a random effects model with a restricted maximum likelihood estimator was used for estimating the combined effect. Funnel plot asymmetry was assessed visually and using Eggers test to estimate the presence of publication and/or small study bias. Results: 14 publications were included in the systematic review. The rates of acute ≥ grade 2 (G2) GU and GI toxicities reported in the included studies range from 0.0-30.0% and 0.0-25.0% respectively. For late ≥G2 GU and GI toxicity, those values are 4.0-51.8% and 0.0-25.0%. The pooled rate of acute GU and GI toxicity ≥G2 were 13% (95% CI: 7-18%) and 2% (95% CI: 0-4%). For late GU and GI toxicity ≥G2 the pooled rates were 25% (95% CI: 14-35%) and 5% (95% CI: 1-9%). The pooled 2-year biochemical recurrence-free survival was 72% (95% CI: 64-92%). Conclusions: SBRT in the re-irradiation of radiorecurrent prostate cancer is overall safe and effective also when applied with a C-arm Linac or an MR Linac. Further prospective data are warranted.

show abstract

Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis

Cited by 5 publications

References 59 publications

Re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after initial definitive radiotherapy – A systematic review and meta-analysis of recent trials

Re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after initial definitive radiotherapy – A systematic review and meta-analysis of recent trials

MRI-Guided Radiation Therapy for Prostate Cancer: The Next Frontier in Ultrahypofractionation

Re-irradiation to the Prostate using stereotactic body radiotherapy (SBRT) after initial definitive Radiotherapy – A systematic review and Meta-analysis of recent trials

Contact Info

Product

Resources

About